Antitumour Anthracyclines: Progress and Perspectives

Spotlight on aldoxorubicin (INNO-206) and its potential in the treatment of soft tissue sarcomas: evidence to date

(2019) Lee D Cranmer   OncoTargets and Therapy

Structural insight into substrate and inhibitor discrimination by human P-glycoprotein

(2019) Amer Alam et al.   SCIENCE

The safety and efficacy of amrubicin in the treatment of previously untreated extensive-disease small-cell lung cancer: a meta-analysis

(2019) Ji-Feng Wu et al.   OncoTargets and Therapy

Intercalating TOP2 Poisons Attenuate Topoisomerase Action at Higher Concentrations

(2019) Mandeep Atwal et al.   MOLECULAR PHARMACOLOGY

Topoisomerases as anticancer targets

(2018) Justine L. Delgado et al.   BIOCHEMICAL JOURNAL

Anthracycline Use for Early Stage Breast Cancer in the Modern Era: a Review

(2018) Sakshi Jasra et al.   CURRENT TREATMENT OPTIONS IN ONCOLOGY

Molecular mechanism of doxorubicin-induced cardiomyopathy – An update

(2018) Kaviyarasi Renu et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Complete genome sequence of Streptomyces peucetius ATCC 27952, the producer of anticancer anthracyclines and diverse secondary metabolites

(2018) Dipesh Dhakal et al.   JOURNAL OF BIOTECHNOLOGY

Molecular structure of human P-glycoprotein in the ATP-bound, outward-facing conformation

(2018) Youngjin Kim et al.   SCIENCE

Molecular mechanism of action of oxazolinoanthracyclines in cells derived from human solid tumors. Part 2

(2018) Marta Denel-Bobrowska et al.   TOXICOLOGY IN VITRO

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

(2018) Freddie Bray et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Novel oxazolinoanthracyclines as tumor cell growth inhibitors—Contribution of autophagy and apoptosis in solid tumor cells death

(2018) Aneta Rogalska et al.   PLoS One

Doxorubicin-conjugated dexamethasone induced MCF-7 apoptosis without entering the nucleus and able to overcome MDR-1-induced resistance

(2018) Kamontip Chaikomon et al.   Drug Design Development and Therapy

Anthracyclines as Topoisomerase II Poisons: From Early Studies to New Perspectives

(2018) Jessica Marinello et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Protective Effects of ω-3 PUFA in Anthracycline-Induced Cardiotoxicity: A Critical Review

(2017) Simona Serini et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Substrate-induced conformational changes in the nucleotide-binding domains of lipid bilayer–associated P-glycoprotein during ATP hydrolysis

(2017) Maria E. Zoghbi et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Structural modifications in the sugar moiety as a key to improving the anticancer effectiveness of doxorubicin

(2017) Marta Denel-Bobrowska et al.   LIFE SCIENCES

Aclarubicin, an anthracycline anti-cancer drug, fluorescently contrasts mitochondria and reduces the oxygen consumption rate in living human cells

(2017) Haruka Iihoshi et al.   TOXICOLOGY LETTERS

Mechanistically elucidating the in vitro safety and efficacy of a novel doxorubicin derivative

(2017) Samaa Alrushaid et al.   Drug Delivery and Translational Research

Pharmacokinetic and Toxicodynamic Characterization of a Novel Doxorubicin Derivative

(2017) Samaa Alrushaid et al.   Pharmaceutics

Candidate Gene Association Studies of Anthracycline-induced Cardiotoxicity: A Systematic Review and Meta-analysis

(2017) Siew Lian Leong et al.   Scientific Reports

Comparative effects of doxorubicin and a doxorubicin analog, 13-deoxy, 5-iminodoxorubicin (GPX-150), on human topoisomerase IIβ activity and cardiac function in a chronic rabbit model

(2016) Nicole E. Frank et al.   INVESTIGATIONAL NEW DRUGS

Identification of the key pathway of oxazolinoanthracyclines mechanism of action in cells derived from human solid tumors

(2016) Marta Denel-Bobrowska et al.   TOXICOLOGY AND APPLIED PHARMACOLOGY

Amrubicin for relapsed small-cell lung cancer: a systematic review and meta-analysis of 803 patients

(2016) Nobuyuki Horita et al.   Scientific Reports

The concomitant management of cancer therapy and cardiac therapy

(2015) Emanuela Salvatorelli et al.   BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES

Phosphatidylinositol- 3-kinase inhibitor induces chemosensitivity to a novel derivative of doxorubicin, AD198 chemotherapy in human bladder cancer cells in vitro

(2015) Dmitriy Smolensky et al.   BMC CANCER

Role of Drug Metabolism in the Cytotoxicity and Clinical Efficacy of Anthracyclines

(2015) Derek Edwardson et al.   CURRENT DRUG METABOLISM

Cytotoxicity and induction of apoptosis by formamidinodoxorubicins in comparison to doxorubicin in human ovarian adenocarcinoma cells

(2015) Agnieszka Marczak et al.   ENVIRONMENTAL TOXICOLOGY AND PHARMACOLOGY

Phase I and pharmacokinetic study of the novel anthracycline derivative 5-imino-13-deoxydoxorubicin (GPX-150) in patients with advanced solid tumors

(2015) Sarah A. Holstein et al.   INVESTIGATIONAL NEW DRUGS

Cellular senescence in aging and age-related disease: from mechanisms to therapy

(2015) Bennett G Childs et al.   NATURE MEDICINE

NGL Viewer: a web application for molecular visualization

(2015) Alexander S. Rose et al.   NUCLEIC ACIDS RESEARCH

Doxorubicin-induced necrosis is mediated by poly-(ADP-ribose) polymerase 1 (PARP1) but is independent of p53

(2015) Hyeon-Jun Shin et al.   Scientific Reports

Natural product and natural product derived drugs in clinical trials

(2014) Mark S. Butler et al.   NATURAL PRODUCT REPORTS

The role of iron in anthracycline cardiotoxicity

(2014) Elena Gammella et al.   Frontiers in Pharmacology

Review and Meta-Analysis of Incidence and Clinical Predictors of Anthracycline Cardiotoxicity

(2013) Marzia Lotrionte et al.   AMERICAN JOURNAL OF CARDIOLOGY

N-benzyladriamycin-14-valerate (AD 198) exhibits potent anti-tumor activity on TRAF3-deficient mouse B lymphoma and human multiple myeloma

(2013) Shanique K E Edwards et al.   BMC CANCER

Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials

(2013)   LANCET

Doxorubicin-Induced Cardiotoxicity: From Bioenergetic Failure and Cell Death to Cardiomyopathy

(2013) Filipa S. Carvalho et al.   MEDICINAL RESEARCH REVIEWS

Drug-induced histone eviction from open chromatin contributes to the chemotherapeutic effects of doxorubicin

(2013) Baoxu Pang et al.   Nature Communications

Oxidative Stress, Redox Signaling, and Metal Chelation in Anthracycline Cardiotoxicity and Pharmacological Cardioprotection

(2012) Martin Štěrba et al.   ANTIOXIDANTS & REDOX SIGNALING

NADPH Oxidases in Heart Failure: Poachers or Gamekeepers?

(2012) Min Zhang et al.   ANTIOXIDANTS & REDOX SIGNALING

Overview of P-glycoprotein inhibitors: a rational outlook

(2012) Kale Mohana Raghava Srivalli et al.   Brazilian Journal of Pharmaceutical Sciences

Anti-Myeloma Effects of the Novel Anthracycline Derivative INNO-206

(2012) E. Sanchez et al.   CLINICAL CANCER RESEARCH

Synthesis and Biological Activities of a 3'-Azido Analogue of Doxorubicin Against Drug-Resistant Cancer Cells

(2012) Shuwen Yu et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Doxorubicin-induced cardiomyopathy: From molecular mechanisms to therapeutic strategies

(2012) Yanti Octavia et al.   JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY

Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems

(2012) Oktay Tacar et al.   JOURNAL OF PHARMACY AND PHARMACOLOGY

Identification of the molecular basis of doxorubicin-induced cardiotoxicity

(2012) Sui Zhang et al.   NATURE MEDICINE

Intravesical valrubicin in patients with bladder carcinoma in situ and contraindication to or failure after bacillus Calmette-Guérin

(2012) Colin P.N. Dinney et al.   UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS

Cardiac safety of adjuvant pegylated liposomal doxorubicin with concurrent trastuzumab: a randomized phase II trial

(2011) D. Rayson et al.   ANNALS OF ONCOLOGY

Effects of quercetin on the bioavailability of doxorubicin in rats: Role of CYP3A4 and P-gp inhibition by quercetin

(2011) Jun-Shik Choi et al.   ARCHIVES OF PHARMACAL RESEARCH

Possibilities to increase the effectiveness of doxorubicin in cancer cells killing

(2011) Veronika Hanušová et al.   DRUG METABOLISM REVIEWS

Anthracycline cardiotoxicity

(2011) Pierantonio Menna et al.   Expert Opinion On Drug Safety

Pharmacogenomic Prediction of Anthracycline-Induced Cardiotoxicity in Children

(2011) Henk Visscher et al.   JOURNAL OF CLINICAL ONCOLOGY

DNA Topoisomerases and Their Poisoning by Anticancer and Antibacterial Drugs

(2010) Yves Pommier et al.   CHEMISTRY & BIOLOGY

Conformational diversity of anthracycline anticancer antibiotics: A density functional theory calculation

(2010) Suhua Zhu et al.   JOURNAL OF MOLECULAR STRUCTURE-THEOCHEM

Protection from Doxorubicin-Induced Cardiomyopathy Using the Modified Anthracycline N-Benzyladriamycin-14-valerate (AD 198)

(2010) C. Cai et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Limitations in doxorubicin production from Streptomyces peucetius

(2010) Sailesh Malla et al.   MICROBIOLOGICAL RESEARCH

Cardiomyocyte death in doxorubicin-induced cardiotoxicity

(2009) Yi-Wei Zhang et al.   ARCHIVUM IMMUNOLOGIAE ET THERAPIAE EXPERIMENTALIS

NADPH oxidases participate to doxorubicin-induced cardiac myocyte apoptosis

(2009) Mylène Gilleron et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Targeting Angiogenesis via a c-Myc/Hypoxia-Inducible Factor-1 -Dependent Pathway in Multiple Myeloma

(2009) J. Zhang et al.   CANCER RESEARCH

Fifty Years of Chemical Research at Farmitalia

(2009) Federico-Maria Arcamone   CHEMISTRY-A EUROPEAN JOURNAL

New Developments in Anthracycline-Induced Cardiotoxicity

(2009) A. Mordente et al.   CURRENT MEDICINAL CHEMISTRY

Synthesis and biological properties of oxazolinodaunorubicin—a new derivative of daunorubicin with a modified daunosamine moiety

(2009) Malgorzata Lukawska et al.   INVESTIGATIONAL NEW DRUGS

Induction of premature senescence in cardiomyocytes by doxorubicin as a novel mechanism of myocardial damage

(2008) Yasuhiro Maejima et al.   AGING CELL

Nonpegylated Liposomal Doxorubicin (TLC-D99), Paclitaxel, and Trastuzumab in HER-2-Overexpressing Breast Cancer: A Multicenter Phase I/II Study

(2008) J. Cortes et al.   CLINICAL CANCER RESEARCH

Albumin as a drug carrier: Design of prodrugs, drug conjugates and nanoparticles

(2008) Felix Kratz   JOURNAL OF CONTROLLED RELEASE

New Insight Into Epirubicin Cardiac Toxicity: Competing Risks Analysis of 1097 Breast Cancer Patients

(2008) Marianne Ryberg et al.   JNCI-Journal of the National Cancer Institute

Cellular Mechanisms of Resistance to Anthracyclines and Taxanes in Cancer: Intrinsic and Acquired

(2008) A. Jo Chien et al.   SEMINARS IN ONCOLOGY